07:00 , Jun 8, 2015 |  BC Week In Review  |  Clinical News

CRLX101: Additional Phase Ib/IIa data

Data from 18 patients with third- through sixth-line metastatic RCC in a dose-escalation, U.S. Phase Ib/IIa trial showed that CRLX101 plus Avastin bevacizumab led to an ORR of 22%, including 4 partial responses, and a...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

CRLX101 regulatory update

FDA granted Fast Track designation to Cerulean’s CRLX101 to treat metastatic renal cell carcinoma (RCC) in combination with Avastin bevacizumab following progression through 2-3 prior lines of therapy. CRLX101, a dual inhibitor of topoisomerase I...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

CRLX101: Additional Phase Ib/IIa data

A dose-escalation, U.S. Phase Ib/IIa in 22 patients with metastatic RCC showed that CRLX101 plus Avastin bevacizumab met the primary endpoint of >=50% of patients achieving 4 months of progression-free survival (PFS). Median PFS was...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Clinical News

CRLX101: Phase Ib data

Data from the Phase Ib portion of an open-label, dose-escalation, U.S. Phase Ib/II trial in non-metastatic rectal cancer patients showed that 12 and 15 mg/m 2 CRLX101 plus chemoradiotherapy led to no dose-limiting toxicities (DLTs)....
18:40 , Dec 18, 2014 |  BC Innovations  |  Tools & Techniques

Neutralizing the negatives of RNAi

Despite years of attempts with liposomes, nanoparticles and conjugation strategies, delivery of siRNA to organs beyond the liver remains the biggest hurdle to use of the technology for a host of diseases. A UCSD group...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
07:00 , Jun 16, 2014 |  BC Week In Review  |  Clinical News

CRLX101: Interim Phase Ib/IIa data

Interim data from 12 patients with metastatic RCC in a dose-escalation, U.S. Phase Ib/IIa trial showed that CRLX101 plus Avastin bevacizumab led to a median progression-free survival (PFS) rate of 7.6 months, which Cerulean said...
07:00 , Apr 14, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Gilead Sciences Inc. (NASDAQ:GILD) was up $0.03 to $72.23 on Monday after FDA accepted and granted Priority Review for an NDA for an oral, once-daily, fixed-dose combination of the company's Sovaldi sofosbuvir and...
00:26 , Apr 11, 2014 |  BC Extra  |  Financial News

Cerulean raises $59.5 million in IPO

Cerulean Pharma Inc. (NASDAQ:CERU) raised $59.5 million in an IPO through a bumped-up number of shares below its proposed price range. The company sold 8.5 million shares at $7, which values Cerulean at $133.1 million....
23:42 , Mar 31, 2014 |  BC Extra  |  Financial News

Cancer play Cerulean sets IPO terms

Cerulean Pharma Inc. (Cambridge, Mass.) amended its IPO on NASDAQ and now plans to sell 5 million shares at $11-$13. At the $12 midpoint, the company would raise $60 million and be valued at $171.7...